Clinical trials: Heart Rhythm Disorder
Atrial Fibrillation
Patient Convenience Study- NIS RELATE
The aim of this non-interventional study is to describe patient's perception of anticoagulant treatment when using Pradaxa® to prevent stroke and systemic embolism while suffering from atrial fibrillation (according to its…
- Trial name
- NCT02849509
- Testing
- Pradaxa (dabigatran), Vitamin K antagonist
- Where
- 50 sites in Indonesia, Malaysia and 3 more
- Volunteers
- 1,313 people
- Sponsor
- Boehringer Ingelheim
Atrial Fibrillation
STOP Persistent AF
To demonstrate safety and effectiveness of the Arctic Front Advance™ and Freezor MAX® Cardiac CryoAblation Catheters for the treatment of drug refractory recurrent symptomatic persistent atrial fibrillation (AF).
- Trial name
- NCT03012841
- Testing
- Arctic Front Advance Cardiac CryoAblation Catheter
- Where
- 25 sites in United States, Canada and 1 more
- Volunteers
- 186 people
- Sponsor
- Medtronic Cardiac Ablation Solutions
Atrial Fibrillation
Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque
Vitamin K-antagonists (VKA) such as warfarin are the most widely used blood thinners for irregular heart beats like atrial fibrillation.
- Trial name
- NCT02090075
- Testing
- apixaban, warfarin
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Atrial Fibrillation
Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF)
When the upper chambers of a person's heart receive or generate irregular electrical signals, it causes abnormal rhythm in the heartbeat. This is called atrial fibrillation.
- Trial name
- NCT02943785
- Testing
- Edoxaban-based Regimen, VKA-based Regimen
- Where
- 230 sites in United States, Austria and 12 more
- Volunteers
- 1,426 people
- Sponsor
- Daiichi Sankyo
Arrhythmias, Cardiac
Reveal In-Office Implants
The purpose of this study is to gather evidence about the safety and feasibility of performing the implant procedure for the Reveal Insertable Cardiac Monitor (ICM) in an office or clinic setting rather than the traditional…
- Trial name
- NCT01168427
- Testing
- Reveal® DX or Reveal® XT Insertable Cardiac Monitor
- Where
- 9 sites in United States
- Volunteers
- 66 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure